Adherence to Universal Aspirin Compared to Screening Indicated Aspirin for Prevention of Preeclampsia
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
There are data showing that a majority of pregnant women may not be accurately identified as
high risk through screening and therefore, not receiving prophylactic low dose aspirin as
recommended. This leads to missing many patients who would benefit from aspirin
administration. Aspirin is an effective, affordable and safe intervention and its universal
use in pregnancy has been proposed as the answer to help mitigate risk of significant
morbidity from preeclampsia. However, adherence to aspirin in women at low risk compared to
those deemed at high risk of preeclampsia has never been studied. One of the arguments
against universal aspirin administration is the concern that universal receipt would change
the compliance in those at high risk although there are no data to support this concern. To
address the lack of data on differences in adherence, our goal in this proposal is to assess
whether there is a difference in adherence to low dose aspirin (81 mg) in women at high risk
of preeclampsia as indicated by USPSTF risk algorithm when compared to those women randomized
to universal use.